Hologic is a key participant in the $70.92B point-of-care diagnostics market by 2032, leveraging the CMS ACCESS Model launching July 2026 to expand AI-driven imaging platforms. The company also launched 'Ultimate Defense', a U.S. campaign urging routine Pap+HPV screening to counter rising underscreening and potentially boost assay volumes.